Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market
First Data Cut Shows 83% Efficacy Against Infection
Executive Summary
Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.
You may also be interested in...
GSK Exceeded Expectations In 2022, Now Looking For Edge Over Pfizer In RSV Battle
Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.
Moderna Chalks Up Industry Milestone With mRNA Cancer Vaccine Efficacy Success
Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.
RSV Market Shake Up Starts As Sanofi And AZ’s Beyfortus Wins First Approval
The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.